Reimbursement Briefs: Medicare Part B, PCORI Research
This article was originally published in The Pink Sheet Daily
MedPAC will analyze alternatives for Medicare Part B to use “least costly alternative” payment method in lieu of legislative authority; OIG says Part B dispensing fees are too high; PCORI releases draft proposal on research review.
You may also be interested in...
Developing alternatives to the ASP-based reimbursement system for Medicare Part B drugs may become increasingly important to ensure the program will benefit from lower-cost biosimilars, Georgetown’s Jack Hoadley points out.
The Centers for Medicare and Medicaid Services has officially notified its contractors to stop using an option to limit payments for Medicare Part B drugs to the "least costly alternative" in a therapeutic class
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.